In a Phase I clinical study involving multiple advanced solid tumors, RG6292 effectively depleted Treg cells in peripheral blood and tumor tissues both as a monotherapy and in combination with the PD-L1 inhibitor Atezolizumab (121). The gene discussed is CD274; the disease is neoplasm.